Prof. L.V. Zhuravlyova, N.V. Sokolnikova, T.A. Rogachova
Kharkiv National Medical University
Currently, all over the world, type 2 diabetes mellitus and the heart failure are developing into an epidemic. For the first time, diabetic cardiomyopathy as an independent diagnostic unit was described in 1972 by Shirley Rubler and colleagues. Currently, the most common phenotype of cardiomyopathy in diabetes is the restrictive type, which is characterized by the presence of diastolic left ventricular myocardial dysfunction and heart failure with preserved systolic function of the left ventricular myocardium. It was unexpected for the scientific world that tight glycemic control with insulin and sulfonylureas did not lead to the expected reduction in the risk of severe heart failure and cardiovascular death in type 2 diabetes mellitus. The effect of antidiabetic drugs on the risk of developing cardiovascular complications is being studied in an increasing number of clinical studies. In this review, we will try to summarize the main issues of the modern treatment of type 2 diabetes and the effect of sugar-lowering drugs on the development of heart failure.
Key Words: diabetes mellitus, heart failure, diabetic cardiomyopathy, Metformin, glitazones, incretins, sodium glucose transporter inhibitors 2.